fbpx
QQQ
-0.45
326.21
-0.14%
DIA
-4.92
352.74
-1.41%
SPY
-3.82
421.92
-0.91%
TLT
-0.78
138.60
-0.57%
GLD
-0.01
172.15
-0.01%

UK Recommends NHS Reimburse GW Pharma's CBD-Based Epilepsy Drug

November 12, 2019 6:37 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
UK Recommends NHS Reimburse GW Pharma's CBD-Based Epilepsy Drug

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announced Sunday that two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service. 

What Happened

Epidiolex, known as Epidyolex in Europe, and Sativex were approved by the NHS for the treatment of epilepsy and multiple sclerosis, respectively.

Doctors will be able to prescribe Epidyolex, an oral CBD solution, for children with two types of severe epilepsy, Lennox Gastaut syndrome and Dravet syndrome.

Sativex is a mouth spray containing a mixture of THC and CBD. 

Related Story: Exclusive: Leafly Launches Cannabis Lab Testing Certification Program

Why It’s Important

"This is a momentous occasion for U.K. patients and families who have waited for so many years for rigorously tested, evidenced and regulatory approved cannabis-based medicines to be reimbursed by the NHS," Chris Tovey, GW’s chief operating officer, said in a statement. 

“This is proof that cannabis-based medicines can successfully go through extensive randomized placebo-controlled trials and a rigorous NICE evaluation process to reach patients. I am hugely proud of the entire GW team for achieving this milestone in the country where the company was founded and where both of these medicines were developed and are manufactured.”

GW Pharma shares were down 3.38% at $109.40 at the close Tuesday. 

Photo by Javier Hasse.


Related Articles

Jazz Pharmaceuticals Closes On Acquisition Of GW Pharma, Adds CBD Drug Epidiolex To Portfolio

The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH). read more

Earnings Roundup: Neptune, Item9, GW Pharmaceuticals

Neptune Revenue Declines 63% YoY, Shifts To CPG And Branded Products read more

Canopy Growth Sues GW Pharma, Alleges Unauthorized Use Of Intellectual Property

Canadian cannabis giant Canopy Growth Corp (NYSE: CGC) filed an federal lawsuit last week against Britain’s GW Pharma (NASDAQ: GWPH). read more

GW Pharma Details Positive Results Of Epidiolex Study In Patients With TSC-Related Seizures

GW Pharmaceuticals plc (NASDAQ: GWPH) said Monday that the results of the company’s positive Phase 3 clinical trial of Epidiolex oral solution in seizures related to tuberous sclerosis complex were published in JAMA Neurology.   read more